Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon Aug 16, 2020 9:25pm

86 Views

Post# 31415855

RE:RE:RE:RE:RE:RE:Rapid Growth of Isotrention Market in Q1/20

I have owned a dozen companies that had the option to buy back shares and only 1 has ever done it to any degree. Let's hope Cipher actually starts to buy back shares right out of the gate until the feel it's shares are fairly priced. You are correct in that this stock will jump if the company starts to accumulate the few thousand shares every week that are sold at market.

Bullboard Posts

E3 inches closer to Alberta's first lithium production plant